Rhythm Pharmaceuticals, Inc. (RYTM)
RYTM Stock Price Chart
Explore Rhythm Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze RYTM price movements and trends.
RYTM Company Profile
Discover essential business fundamentals and corporate details for Rhythm Pharmaceuticals, Inc. (RYTM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Oct 2017
Employees
283.00
Website
https://www.rhythmtx.comCEO
David P. Meeker
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
RYTM Financial Timeline
Browse a chronological timeline of Rhythm Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$0.72, while revenue estimate is $50.68M.
Earnings released on 5 Aug 2025
EPS came in at -$0.75 falling short of the estimated -$0.66 by -13.64%, while revenue for the quarter reached $48.50M , missing expectations by -5.51%.
Earnings released on 7 May 2025
EPS came in at -$0.81 falling short of the estimated -$0.69 by -17.39%, while revenue for the quarter reached $32.70M , missing expectations by -24.44%.
Earnings released on 26 Feb 2025
EPS came in at -$0.72 falling short of the estimated -$0.69 by -4.35%, while revenue for the quarter reached $41.83M , beating expectations by +8.69%.
Earnings released on 5 Nov 2024
EPS came in at -$0.73 surpassing the estimated -$0.80 by +8.75%, while revenue for the quarter reached $33.25M , missing expectations by -7.45%.
Earnings released on 6 Aug 2024
EPS came in at -$0.55 surpassing the estimated -$0.70 by +21.43%, while revenue for the quarter reached $29.08M , beating expectations by +1.00%.
Earnings released on 7 May 2024
EPS came in at -$2.35 falling short of the estimated -$2.34 by -0.43%, while revenue for the quarter reached $25.97M , missing expectations by -9.81%.
Earnings released on 22 Feb 2024
EPS came in at -$0.70 matching the estimated -$0.70, while revenue for the quarter reached $24.23M , missing expectations by -4.52%.
Earnings released on 7 Nov 2023
EPS came in at -$0.76 matching the estimated -$0.76, while revenue for the quarter reached $22.50M , missing expectations by -14.60%.
Earnings released on 1 Aug 2023
EPS came in at -$0.82 falling short of the estimated -$0.80 by -2.50%, while revenue for the quarter reached $19.22M , missing expectations by -16.28%.
Earnings released on 2 May 2023
EPS came in at -$0.92 falling short of the estimated -$0.71 by -29.58%, while revenue for the quarter reached $11.47M , missing expectations by -5.37%.
Earnings released on 1 Mar 2023
EPS came in at -$0.75 surpassing the estimated -$0.82 by +8.54%, while revenue for the quarter reached $8.79M , beating expectations by +21.77%.
Earnings released on 8 Nov 2022
EPS came in at -$0.79 surpassing the estimated -$1.01 by +21.78%, while revenue for the quarter reached $4.28M , missing expectations by -10.02%.
Earnings released on 2 Aug 2022
EPS came in at -$0.89 falling short of the estimated -$0.79 by -12.66%, while revenue for the quarter reached $9.07M , beating expectations by +253.38%.
Earnings released on 3 May 2022
EPS came in at -$1.05 falling short of the estimated -$0.98 by -7.14%, while revenue for the quarter reached $1.50M , missing expectations by -34.87%.
Earnings released on 1 Mar 2022
EPS came in at -$0.85 surpassing the estimated -$1.00 by +15.00%, while revenue for the quarter reached $1.82M , beating expectations by +6.75%.
Earnings released on 2 Nov 2021
EPS came in at -$0.70 surpassing the estimated -$0.84 by +16.67%, while revenue for the quarter reached $1.03M , beating expectations by +9.36%.
Earnings released on 3 Aug 2021
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.67%, while revenue for the quarter reached $274.00K , meeting expectations.
Earnings released on 3 May 2021
EPS came in at $0.90 surpassing the estimated -$0.23 by +492.23%, while revenue for the quarter reached $35.00K , meeting expectations.
Earnings released on 1 Mar 2021
EPS came in at -$0.79 surpassing the estimated -$0.81 by +2.47%.
Earnings released on 2 Nov 2020
EPS came in at -$0.77 surpassing the estimated -$0.83 by +7.23%.
RYTM Stock Performance
Access detailed RYTM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.